CDT Equity Inc.
Close on Oct 19, 2026
- Market cap
- $99.14K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
CDT Equity has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements CDT Equity filed with the SEC
Equity Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Equity Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Equity Announces Debt Update and New Loan Facility
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Equity Inc. Announces Receipt of Nasdaq Deficiency Letter
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Equity Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Equity Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
to Change Name to CDT Equity Inc.
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Conduit Pharmaceuticals to Revolutionize Drug
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF CONDUIT PHARMACEUTICALS LIMITED
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K/A
Unaudited Condensed Financial Statements of Conduit Pharmaceuticals Limited:
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K/A
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K/A
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF CONDUIT PHARMACEUTICALS LIMITED
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
and Unreviewed Condensed Financial Statements of Conduit Pharmaceuticals Limited:
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
(AND UNREVIEWED WITH RESPECT TO CONDUIT) PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K
Canyon Acquisition Corp. Announces Stockholder
Shareholder vote results · Other events · EX-99.1 to Form 8-K
CANYONACQUISITION CORP. ANNOUNCES POSTPONEMENT OF
Other events · EX-99.1 to Form 8-K
CANYONACQUISITION CORP. ANNOUNCES POSTPONEMENT OF
Other events · EX-99.1 to Form 8-K
Prospectus dated August 11, 2023)
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Declares Form S-4 Registration Statement “Effective” for Proposed Business Combination of Murphy Canyon Acquisition Corp.
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals to Become a Publicly Traded Company via Merger with Murphy Canyon Acquisition Corp.
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K